Medicare Part D covers Ozempic when it is prescribed for type 2 diabetes, which is its FDA-approved indication. It does not cover Ozempic prescribed purely for weight loss. This is not a plan-by-plan preference — federal law has long excluded drugs used for weight loss from Part D coverage, so the indication on your prescription determines everything.
This is one part of getting a GLP-1 covered. For the full picture, see GLP-1 Insurance Coverage: The Complete Guide.
The rule that decides this
The Social Security Act sets out categories of drugs that Part D plans may exclude, and one of those categories is agents used for weight loss. That exclusion is why the question of Medicare and GLP-1 coverage has always turned on why the drug was prescribed rather than which drug it is.
Ozempic is approved for type 2 diabetes. Prescribed for that, it sits squarely inside what Part D covers. The same molecule sold as Wegovy, approved for weight management, has historically fallen on the wrong side of that exclusion.
So the practical answer for most people is straightforward. If you have a type 2 diabetes diagnosis coded in your record and Ozempic is prescribed to manage it, Part D coverage is generally available, subject to your plan’s formulary and any prior authorization it requires.
What “covered” still requires
Coverage in principle is not the same as the pharmacy handing it over.
Your specific Part D plan has a formulary, and Ozempic may sit on a higher cost tier. It may carry a prior authorization requirement, meaning your prescriber has to confirm the diabetes diagnosis before the plan pays. It may carry step therapy, meaning the plan wants you to have tried metformin or another agent first. And it may carry quantity limits.
Check your plan’s formulary directly rather than assuming. Plans change their formularies annually, and a drug covered last year can move tiers or acquire a prior authorization flag in January.
If you have obesity but not diabetes
This is where people run into the wall. A prescriber can legally write Ozempic off-label for weight management, but Part D will not pay for it on that basis, and a prior authorization asking the plan to cover it for weight loss will be denied.
The routes that remain are self-pay, manufacturer savings programs — though these frequently exclude anyone enrolled in a federal program including Medicare, which catches a lot of people by surprise — or a different drug with an indication your plan does cover.
That last option is worth exploring with your prescriber, because the landscape shifted when GLP-1 medications began earning approvals for conditions other than weight loss.
Medicare Advantage plans
If you have Medicare Advantage with drug coverage, the same federal exclusion applies to your Part D benefit. Some Advantage plans offer supplemental benefits beyond standard Part D, so it is worth asking, but do not assume the exclusion has been waived.
The same statutory exclusion shapes whether Part D covers Wegovy and what the sleep apnea indication changed for Zepbound. All three turn on the indication rather than the molecule, which is explained in why diabetes and obesity coverage differ.
Frequently asked questions
Can my doctor write “type 2 diabetes” to get it covered if I don’t have diabetes?
No. That is a false claim on a federal benefit program and carries serious consequences for both you and the prescriber. Do not ask for it and do not accept it if offered.
I have prediabetes. Does that count?
No. Prediabetes is not the approved indication for Ozempic, and Part D coverage follows the approved indication.
Will Medicare ever cover GLP-1s for weight loss?
The policy has been actively debated and proposals to change it have been floated. Because this area moves, check the current position on Medicare.gov rather than relying on any article, including this one.
Does the manufacturer savings card work with Medicare?
Usually not. Manufacturer copay assistance is generally unavailable to people enrolled in federal health programs. Check the program’s own terms.
What about Part B?
Part B covers drugs administered in a clinical setting. A self-injected weekly pen falls under Part D, not Part B.
My plan covered it last year and stopped. Why?
Formularies reset annually. A tier change, a new prior authorization requirement, or removal from the formulary are all possible at plan year boundaries.
Sources
- Social Security Act §1860D-2(e)(2), excluded drug categories — ssa.gov
- FDA Prescribing Information, Ozempic (semaglutide) injection — accessdata.fda.gov
- Medicare Plan Finder and formulary lookup — medicare.gov